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Abstract
Background: Glioblastoma (GBM) is the most common primary brain malignancy and confers a dismal prognosis.
GBMs harbor glioblastoma-initiating cells (GICs) that drive tumorigenesis and contribute to therapeutic resistance
and tumor recurrence. Consequently, there is a strong rationale to target this cell population in order to develop
new molecular therapies against GBM. Accumulating evidence indicates that Nα-terminal acetyltransferases
(NATs), that are dysregulated in numerous human cancers, can serve as therapeutic targets.
Methods: Microarrays were used to study the expression of several NATs including NAT12/NAA30 in clinical
samples and stem cell cultures. The expression of NAT12/NAA30 was analyzed using qPCR, immunolabeling and
western blot. We conducted shRNA-mediated knockdown of NAT12/NAA30 gene in GICs and studied the effects
on cell viability, sphere-formation and hypoxia sensitivity. Intracranial transplantation to SCID mice enabled us to
investigate the effects of NAT12/NAA30 depletion in vivo. Using microarrays we identified genes and biochemical
pathways whose expression was altered upon NAT12/NAA30 down-regulation.
Results: While decreased expression of the distal 3’UTR of NAT12/NAA30 was generally observed in GICs and
GBMs, this gene was strongly up-regulated at the protein level in GBM and GICs. The increased protein levels
were not caused by increased levels of the steady state mRNA but rather by other mechanisms. Also, shorter
3’UTR of NAT12/NAA30 correlated with poor survival in glioma patients.
As well, we observed previously not described nuclear localization of this typically cytoplasmic protein. When
compared to non-silencing controls, cells featuring NAT12/NAA30 knockdown exhibited reduced cell viability,
sphere-forming ability, and mitochondrial hypoxia tolerance. Intracranial transplantation showed that knockdown
of NAT12/NAA30 resulted in prolonged animal survival.
Microarray analysis of the knockdown cultures showed reduced levels of HIF1α and altered expression of several
other genes involved in the hypoxia response. Furthermore, NAT12/NAA30 knockdown correlated with
expressional dysregulation of genes involved in the p53 pathway, ribosomal assembly and cell proliferation.
Western blot analysis revealed reduction of HIF1α, phospho-MTOR(Ser2448) and higher levels of p53 and GFAP in
these cultures.
Conclusion: NAT12/NAA30 plays an important role in growth and survival of GICs possibly by regulating hypoxia
response (HIF1α), levels of p-MTOR (Ser2448) and the p53 pathway.
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Background
Glioblastoma multiforme (GBM) is the most common
and the most aggressive primary brain cancer. The
average annual age-adjusted incidence rate is ~3 per
100.000 person-years [1]. Despite multimodal therapy
and inclusion of temozolomide, the overall survival
remains dismal [2, 3]. This grim scenario mandates a
pivotal shift in our approaches to develop new therapy
as well as understanding the underlying disease mecha-
nisms. During the last decade the GBM field has shown
interest in a subgroup of cells harbored within these
tumors with stem cell characteristics [4–6] that forms
invasive tumors, similar to the tumor of origin, upon
orthotopic xenotransplantation [7]. These cells are
commonly referred to as glioblastoma-initiating cells
(GICs) and deemed important for the characteristics of
GBM. They possess enhanced invasive properties [8, 9],
promote tumor angiogenesis [10–12] and are resistant
to irradiation [13] and chemotherapy [14, 15]. Thus,
there is a strong rationale for validating potential mo-
lecular targets in GICs.
Dysregulation of co- or post-translational protein
modifications is a trait of many human cancers. Nα- or
N-terminal (Nt-) acetylation is one of the most com-
mon covalent modifications of all soluble human pro-
teins [16] and occurs predominantly co-translationally
[17]. N-terminal acetyltransferases (NATs) or Nα-
acetyltransferases (NAAs) are arranged in complexes
and believed to target ~80-90 % of all soluble human
proteins [17, 18]. Six NAT complexes have been identi-
fied in humans, NAT-A – NAT-F and each complex con-
sists of one catalytic subunit and auxiliary subunit(s) [16].
With an increasing body of knowledge about their diverse
functions, substrates and downstream targets, NATs are
emerging as potential targets in several cancers [16].
Knockdown studies targeting NATs in various malignan-
cies including colon [19], thyroid [20] and hepatocellular
cancers [21] have shown that depletion of the catalytic
subunit causes a less aggressive phenotype with reduced
cell proliferation and/or increased apoptosis.
NAT12/NAA30 is the catalytic subunit of the NAT-C
complex [22]. Knockdown of each of the NAT-C sub-
units, led to p53-dependent apoptosis in HeLa and
colon carcinoma cell lines with the strongest phenotype
observed with depletion of NAT12/NAA30 [23]. The lat-
ter study also pointed out mammalian target of rapamy-
cin (MTOR) as a substrate for NAT-C. Another report
also suggested TOR as a target of NAT-C activity [24].
In the present study we investigated the expression of
NAT12/NAA30 in GBM tissue samples, GICs, normal
brain tissue, and neural stem cells (NSCs) from the
adult human brain as well as in a neural fetal cell line
(NFCs). Using immunolabeling, we revealed a hitherto
undescribed nuclear localization of NAT12/NAA30
protein. To study the function of NAT12/NAA30, we
performed gene knockdown using RNA interference
(RNAi) technology. Knockdown of NAT12/NAA30 re-
sulted in markedly reduced cell viability and sphere-
forming ability of GICs. To study genes and pathways
downstream of NAT12/NAA30, we used microarray
analysis and western blot. This enabled us to identify
several pathways such as p53, ribosomal assembly,
hypoxia response and cell proliferation regulated by
NAT12/NAA30. Furthermore, we documented a reduc-
tion of phospho-MTOR (Ser2448) and increased levels
of p53 and glial fibrillary acidic protein (GFAP) in the
knockdown cultures. We show that intracranial trans-
plantations into severe combined immunodeficient
(SCID) mice of GICs featuring NAT12/NAA30 knock-
down, resulted in a significant prolongation of animal
survival compared to controls.
Results
Expression of NAT12/NAA30 in brain tissues, GBM, NSCs,
GICs and NFCs
To investigate the expression of NAT12/NAA30 in GBM
tumor biopsies, normal human brain, NSCs, GICs and
NFCs we used microarrays, real-time quantitative
reverse-transcription PCR (qPCR), western blots, immu-
nolabeling and public data mining.
Microarray analysis was performed on GIC cultures
from seven patients, ten NSC cultures from five pa-
tients, two GBM biopsies, two normal brain tissue
samples and one NFC culture. NSC cultures were iso-
lated from four brain regions: the subventricular zone
(SVZ), hippocampus (HPC), white- and grey matter
(WM and GM respectively). Normal tissues were from
WM and GM.
NAT12/NAA30 expression (measured with the 3’ ter-
minal ILMN_2128087 reporter) was moderately but
significantly higher in NSC compared to GIC cultures
(Fig. 1a). It was also higher in the cell cultures compared
to tissues (Additional file 1: Figure S1). We also analyzed
the expression of several other NATs in the same set of
microarrays and found that NAT5, NAT14, NAT10 and
NAT9 were among the most abundant NATs in the ana-
lyzed cell cultures and tissues (Fig. 1b). NAT12/NAA30
was among the relatively lowly expressed NATs (Fig. 1b).
K-means clustering (Additional file 2: Figure S2) showed
that NAT12/NAA30 was co-expressed with NAT1,
NAT13 and NAT5. Hierarchical clustering with distance
matrix using Pearson correlation as a distance measure
(Fig. 1c) revealed that NAT12/NAA30 was highly co-
expressed with NAT8, NAT8B, NAT1, NAT6, NAT13,
and co-expressed with NAT2 and NAT5 (Fig. 1c). Several
NATs from this group had significantly lower expression
in GIC than in NSC cultures (NAT12, NAT6, NAT8 and
NAT8B). Several other NATs such as NAT9, NAT10,
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NAT14 and NAT15 were expressed to a similar degree in
GIC and NSC cultures. NAT8L was the only NAT that
was significantly up-regulated in GIC cultures and GBM
(Additional file 1: Figure S1).
qPCR analysis was used to validate the microarray
results. We used seven sets of oligonucleotides that cov-
ered both coding (A-C) and non-coding (D-G) regions
of the gene (Fig. 1d-e, Additional file 3) to investigate
NAT12/NAA30 expression in seven GIC cultures, two
NSC cultures and one NFC culture.
qPCR revealed that the relative expression of the cod-
ing regions of NAT12/NAA30 was very variable between
different GIC cultures. However, the average expression
values were similar in GIC and NSC cultures as shown
by qPCR with oligonucleotides corresponding to the
coding regions of the gene (Fig. 1d; Oligonucleotide sets
A and B, Additional file 4) and Taqman probes corre-
sponding to the exons (Fig. 1f ).
Interestingly, when oligonucleotides corresponding to
the 3’UTR (C, E, F and G) were used (Fig. 1e), qPCR
analysis showed that NAT12/NAA30 expression was
reduced in GIC cultures (Fig. 1d). We observed almost
complete absence of expression (97 % reduction) in GIC
cultures when using oligonucleotide set G, which corre-
sponds to the most distal region of the 3’UTR (Fig. 1d,
Additional file 4).
Western blot. NAT12/NAA30 protein expression in
NSC and GIC cultures, GBM tissues and NFCs was in-
vestigated using western blots (Fig. 1g). We detected a
stronger band at around 50 kDa in the GICs although
the expected sizes of the two isoforms of the protein
were 35 and 39 kDa (Fig. 1g). This might indicate either
protein modification or the presence of a different iso-
form in the GICs. Bands of comparable sizes were de-
tected using another antibody and recombinant protein
confirming that the correct bands were detected (results
not shown). Western blot analysis revealed that NAT12/
NAA30 expression in GIC cultures was significantly
higher than in NSC cultures (Fig. 1g) although this was
not observed at RNA level (Fig. 1a, d and f ).
Survival analysis. Public database mining was done
using data from the REMBRANDT database (https://
caintegrator.nci.nih.gov/rembrandt/) where 3 probes
were used to measure the expression of NAT12/NAA30
covering different parts of the transcript (Fig. 1e;
microarray probes ending with “_at”).
Interestingly, the 3’UTR of NAT12/NAA30 seemed to
be universally down-regulated in glioma tissue samples.
This was in accordance with our data obtained by both
microarray analysis and qPCR (Fig. 1a and d). Glioma
patients with decreased expression of the distal 3’UTR
end of the NAT12/NAA30 transcript (Probe: 225679_at,
Fig. 1e) had significantly shorter survival (Additional
file 5: Figure S3A), while the increased expression of
the coding regions of this gene (Probes: 228322_at,
228321_at, Fig. 1e) did not seem to correlate with pa-
tient survival (Additional file 5: Figure S3B-C). For
comparison, we also checked the association between
the expression levels of other NATs in glioma tissues
and patient survival. Increased expression of each of
NAT1, NAT2 and NAT10 correlated negatively with
patient survival in the group of “all gliomas” patients
(Additional file 5: Figure S3D-F).
Immunolabeling. We tested the expression of the
NAT12/NAA30 protein in three GIC and three NSC
cultures, and in frozen sections from two GBMs and
two normal brain tissues (Fig. 2 and Additional file 6:
FigureS4). NAT12/NAA30 protein was barely detect-
able in samples from normal brain (Fig. 2a, Additional
file 6: Figure S4A) but it was highly up-regulated in the
GBM biopsies (Fig. 2c, Additional file 6: Figure S4B).
GBM tissue sections were co-stained with anti-NAT12/
NAA30 and anti-nestin antibodies (Fig. 2d). This re-
vealed a cell population expressing both proteins
(Fig. 2e). The cells expressing both nestin and NAT12/
NAA30 were detected frequently in GICs (Fig. 2h-j).
(See figure on previous page.)
Fig. 1 Expression of NAT12/NAA30 in GIC and NSC cultures, NFCs, and in GBM and normal brain tissues. a, Expression of NAT12/NAA30 is analysed
by microarray (3’UTR Reporter = ILMN_2128087). Expression is 1.2 fold higher in NSCs than in GICs (p = 0.0281). P values were calculated using the
Mann Whitney test. Due to the small sample size the values were not calculated for tissues and NFCs. b, Box and whiskers plot showing the
expression of the selected NATs in all samples as measured by microarrays. c, Hierarchical clustering (with distance matrix) of the expression
values for selected NAT genes in all samples. d, Expression of NAT12/NAA30 in GIC cultures was calculated using qPCR and the seven sets of
oligonucleotides whose positions are delineated in (e). NSCs were used as a control. P values in this experiment were as following p(A) = 0.641,
p(B) = 0.532, p(C) = 0.033, p(D) = 0.268, p(E) = 0.007, p(F) = 0.012, and p(G) = 0. The bottom and top of each box indicate the 25th and 75th
percentile (the lower and upper quartiles, respectively), and the band near the middle of the box is the 50th percentile (the median). The ends of
the whiskers represent the minimum and maximum of all the data. Additional details of the statistical analysis can be found in Additional file 4.
e. Detailed architecture of the reference sequence of the NAT12/NAA30 transcript (NM_001011713.2) and details on probes and oligonucleotide
positions. f, Relative expression of the coding regions of NAT12/NAA30 in GICs compared to NSCs as measured with Taqman probes. P values for
this analysis were (0.266, 0.970 and 0.672). Additional details of the statistical analysis can be found in Additional file 4. g. Expression of the
NAT12/NAA30 protein in NSC and GIC cultures, GBM and NFCs
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Interestingly, in the GBM sections, NAT12/NAA30 ex-
pressing cells were located in the perivascular spaces
(Fig. 2f ). The same staining pattern was confirmed with
another antibody against NAT12/NAA30 (results not
shown). The observation that NAT12/NAA30 was
highly expressed in cells surrounding blood vessels,
was verified by co-staining with anti-CD31 antibody
(Fig. 2g).
NAT12/NAA30 was previously detected in the cyto-
plasm of various eukaryotic cells [23–26]. However, our
immunolabeling revealed an hitherto unreported nuclear
localization of NAT12/NAA30. The nuclear localization
was consistently detected in all tested GIC cultures but
was more sporadic in the NSC cultures (Fig. 2k-n,
Additional file 6: Figure S4C-F).
NAT12/NAA30 knockdown
In order to study the functional relevance of NAT12/
NAA30 in GICs, we established short hairpin RNA
(shRNA)-mediated knockdown of NAT12/NAA30. We
transduced the GIC culture T65 with lentiviruses har-
boring two different shRNA sequences and obtained
transgenic cell cultures (KD1 and KD2). Non-silencing
(NS) shRNA was used as a control. Knockdown effi-
ciency was assessed with qPCR, western blot and immu-
nolabeling to confirm depletion of NAT12/NAA30
transcript and -protein. The gene knockdown efficiency
was measured with oligonucleotides corresponding to
the coding (A-C) and non-coding (D-G) regions of the
gene (Fig. 1e, Fig. 3a-b). Relative expression of NAT12/
NAA30 was reduced with 60 ± 14 % in KD1 (Fig. 3a)
and 56 ± 3 % in KD2 (Fig. 3b). For this calculation we
used average values for two sets of oligonucleotides (B
and C) corresponding to the coding regions of the gene
(Fig. 1e, Additional file 4). Transcripts corresponding to
the 3’UTR were predominantly not down-regulated in
knockdown cultures KD1 and KD2 as shown by qPCR
using oligonucleotides D-G (Fig. 3a-b).
Western blot showed reduction of NAT12/NAA30
protein levels in both KD1 and KD2 cultures (Fig. 3c).
To quantify the efficiency of knockdown at the protein
level, we used three western blots and two antibodies.
We measured an average reduction of 27 ± 13 % in KD1
and 40 ± 6 % in KD2 (Fig. 3d).
Immunolabeling confirmed reduced protein expres-
sion in GICs featuring NAT12/NAA30 gene knockdown
compared to both untreated control and NS (Fig. 3e).
This was also confirmed with another antibody against
NAT12/NAA30 (results not shown).
Knockdown of NAT12/NAA30 in GICs reduces cell viability
and sphere-forming ability
We investigated the functional effects of the NAT12/
NAA30 knockdown in GICs by measuring cell viability
and sphere-forming ability in NS, KD1 and KD2 cultures.
Values obtained by the XTT assay for the knock-
down cultures were normalized to the NS control. The
number of viable cells was reduced to 58 ± 8 % for
KD1 (p = 0.0314; unpaired t-test with Welch’s correc-
tion) and 43 ± 8 % (p = 0.0172) for KD2 compared to
the NS control. This demonstrated a significant reduc-
tion in cell viability of GICs featuring NAT12/NAA30
knockdown (Fig. 4a).
The number of spheres formed from cells seeded at a
low density (500 cells per well) was 29 ± 7 (p = 0.0472) in
KD1 and 17 ± 2 (p = 0.121) in KD2 compared to 58 ± 10
in the NS control (Fig. 4b-c). Our results thus indicate
that the NAT12/NAA30 knockdown reduced sphere-
forming ability by 50–71 %. The sphere-size was, how-
ever, not affected (results not shown).
Knockdown of NAT12/NAA30 in GICs prolonged survival
of intracranially xenografted mice
To investigate the effect of NAT12/NAA30 knockdown
on GIC growth and tumor formation in vivo we used a
robust orthotopic xenograft model [27, 28]. Cells from
the knockdown cultures KD1 and KD2, and the NS con-
trol culture were transplanted into the right hemisphere
of SCID mice (n = 6 for each group).
Median survival for mice transplanted with NS cells
was 125 days versus 189 for KD1 (p = 0.0192; Log-rank
test) and 143 for KD2 (p = 0.0385) (Fig. 4d). All 6/6 ani-
mals in the NS control group died whereas 2 animals in
KD1 group and 1 in KD2 group did not show any sign
of distress at the end of the observation period of
(See figure on previous page.)
Fig. 2 Immunolabeling with anti-NAT12/NAA30 antibody performed on GIC and NSC cultures, GBM tissues and brain tissue. a, Immunolabeling
of a biopsy from normal human cortex shows no expression of NAT12/NAA30 (red) and nestin (NES, green). b, Hoechst staining showing high
nuclear density in a GBM biopsy. c, Immunolabeling of NAT12/NAA30 (red) in a GBM biopsy. d, Immunolabeling of NES (green) in a GBM biopsy.
e, Extensive staining of both NAT12/NAA30 (red) and NES (green) in a GBM tissue specimen. f, NAT12/NAA30 positive cells are abundant around
vessels. g, Co-staining of NAT12/NAA30 (red) and CD31 (green) confirms that NAT12/NAA30 cells are located in the perivascular niche of the
tumor. Scale bar is 100 μm. h-j, Confocal images of NAT12/NAA30 immunolabeling show that NES (green) and NAT12/NAA30 (red) is co-expressed in
GICs. NES is present in the cytoplasm and NAT12/NAA30 is also found in the nuclei. Scale bar is 20 μm. k-n, Confocal images showing cellular
expression pattern of NAT12/NAA30 (red) in GIC– and NSC cultures. NAT12/NAA30 (red) is predominantly located in the cytoplasm of NSCs but is
consistently present in the nuclei in GIC cultures depicted by the overlap with Hoechst (blue). Scale bar is 20 μm
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200 days. Representative cryosections stained with
Hematoxylin and Eosin (HE) from the xenograft brains
are shown in Additional file 6: Figure S4G.
Knockdown of NAT12/NAA30 in GICs decreased
mitochondrial hypoxia tolerance
The ability to tolerate hypoxic conditions is a well known
trait of GICs and it contributes to the tumor cells’ evasion
of apoptosis [29]. It has previously been shown that
NAT12/NAA30 is involved in regulation of apoptosis [23].
Mitochondrial depolarization is an early step in pro-
grammed cell death. To test if down-regulation of
NAT12/NAA30 influences mitochondrial properties, such
as mitochondrial hypoxia tolerance, we compared the
mitochondrial response to acute severe hypoxia in NS and
knockdown cultures, KD1 and KD2.
Baseline recordings of mitochondrial membrane
potential (ΔΨm) were stable in all cells. Increase in
Rh123 fluorescence, indicating mitochondrial mem-
brane depolarization, was seen in all three groups
within 3–5 min of hypoxia. Compared to the NS con-
trol, there was a steeper increment of the fluorescent
signal in KD1 and KD2 (Fig. 4e-f; KD1 and KD2 vs. NS,
both p < 0.01, one-way ANOVA). The remaining ΔΨm
was released upon addition of the protonophore FCCP.
The FCCP response of the control cells was almost
twice that of the NAT12/NAA30 knockdown cells (rela-
tive fluorescence increase: NS 1.63; KD1 0.92; KD2
0.95) indicating that the remaining mitochondrial
membrane potential after hypoxia was higher in the NS
control cells than in KD1 and KD2. The difference was,
however, not statistically significant (Fig. 4e-f; p = 0.07,
two-way ANOVA).
Identification of genes and biological pathways
downstream from NAT12/NAA30
To identify genes and biological pathways downstream
from NAT12/NAA30, we used microarrays, qPCR and
western blot.
Microarray analysis showed that 661 Illumina probes
identified transcripts that were differentially regulated
(1.5-fold change) in GICs featuring NAT12/NAA30
knockdown (Additional file 7). Of these 464 were recog-
nized and analyzed by the DAVID functional annotation
tool [30, 31]. This analysis revealed that the NAT12/
NAA30 knockdown had a significant effect (p = 3.00E-
05) on the expression of genes coding for ribosomal
proteins (Additional file 7). Many of these were directly
involved in protein translation (Additional file 7). KEGG-
pathway analysis identified three significantly dysregu-
lated pathways: 1) Ribosome (13 genes, p = 5.6E-06), 2)
p53 pathway (8 genes, p = 3.1E-03) and 3) Sphingolipid
metabolism (6 genes, p = 4.8E-03) (Additional file 8:
Figure S5–S7 and Additional file 7).
A more detailed analysis of the p53 pathway revealed
that the expression of eight genes in this pathway was
differentially regulated in the NAT12/NAA30 knock-
down cultures. These genes were involved in apoptosis,
cell cycle arrest and DNA repair (Additional file 8:
Figure S6 and Additional file 7). Former studies have
shown that knockdown of the NAT-C complex leads to
reduced proliferation and p53-dependent cell death in
human cancer cell lines [23]. Starheim et al. reported
increased levels of total p53, phospho-p53 (Ser37) and
apoptosis in HeLA cells featuring NAT12/NAA30
knockdown [23]. In our knockdown cultures, western
blot showed a slight increment in the total p53 (Fig. 5a),
while the levels of the phospho-p53 (Ser37) were not
altered (Additional Additional file 9: Figure S8A). We
could not detect any significant changes in apoptosis in
the knockdown cultures (results not shown).
Ten genes involved in the response to hypoxia (p =
6.80E-03; GOTERM_BP_FAT: response to hypoxia)
were differentially regulated in the knockdown cultures
(Additional file 10: Figure S9 and Additional file 7).
Further analysis of the hypoxia response pathway
showed that the hypoxia induced factor 1α (HIF1α),
potassium large conductance calcium-activated channel
(See figure on previous page.)
Fig. 3 Confirmation of NAT12/NAA30 gene knockdown at RNA and protein level. a-b, Box and whiskers plot of gene expression as measured by
qPCR. The bottom and top of each box indicate the 25th and 75th percentile (the lower and upper quartiles, respectively), and the band near the
middle of the box is the 50th percentile (the median). The ends of the whiskers represent the minimum and maximum of all the data. a, Relative
expression of NAT12/NAA30 in KD1 culture was analysed using seven sets of oligonucleotides designed to cover the whole transcript (for
oligonucleotide position see Fig. 1e). Relative expression (RE) calculated by normalization to the NS culture and the statistical parameters. P values
in this experiment were as follows p(A) = 0.35, p(B) = 0.011, p(C) = 0.001, p(D) = 0.146, p(E) = 0.001, p(F) = 0.915, and p(G) = 0.367. Asterisks
correspond to p values and indicate level of significance. * = (p ≈ 0.01-0.05), ** = (p ≈ 0.001-0.01), *** = (p ≈ 0.0001-0.001), **** = (p < 0.0001).
Additional details of the statistical analysis can be found in Additional file 4. b, The same for KD2 culture. P values in this experiment were as
follows: p(A) = 0.368, p(B) = 0.002, p(C) = 0.019, p(D) = 0.099, p(E) = 0.256, p(F) = 0.167, and p(G) = 0.61. Asterisks correspond to p values and indicate
level of significance. Additional details of the statistical analysis can be found in Additional file 4. c, Western blot showing knockdown of NAT12/
NAA30 protein in KD1 and KD2. d, Quantification of the protein expression from western blots (average of three blots with two different
antibodies) showing relative expression of NAT12/NAA30 protein in knockdown cultures KD1 and KD2 compared to the controls, NS and T65
untransduced. e, Immunolabeling showing expression of NAT12/NAA30 (red) in the two controls, T65 untransduced and T65 NS and reduced
protein levels in KD1 and KD2. Scale bar is 50 μM
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(KCNMA1) and the integrin receptor (ITGA2) (involved
in cell survival and growth via the PI3K pathway) were
down-regulated in the knockdown cultures. HIF1α is
one of the central regulators of transcriptional control
in tumor cells’ response to hypoxic conditions. In
GBM, it is regarded as a key player in tumor progres-
sion and an important factor for the maintenance of
GIC phenotype [32, 33]. Therefore, it was of great
interest to analyze the expression of HIF1α protein in
the NAT12/NAA30 knockdown cultures. Notably, west-
ern blot showed that the levels of HIF1α were de-
creased in the knockdown cultures compared to the
controls (Fig. 5d), thus confirming the microarray
results. The levels of KCNMA1 protein were, however,
not altered in the knockdown cultures (Additional file 9:
Figure S8B). Among the up-regulated genes were the
growth inhibiting factor metallothionein 3 (MT3), CD24,
chemokine receptor type 4 (CXCR4) and chemokine
ligand 2 (CCL2) (Additional file 10: Figure S9 and
Additional file 7).
Among other genes differentially expressed in the
NAT12/NAA30 knockdown cultures, were groups of
genes coding for: a) proteins involved in organization of
nucleosomes (11 genes, p = 1.1E-04), b) cell proliferation
(22 genes, p = 3.50E-03) and c) protein kinase activity
(22 genes, p = 1.8E-04) (Additional file 7).
Previous studies have identified MTOR as a potential
substrate for the NAT-C complex [23] and a down-
stream target of NAT-C activity [24]. Microarray ana-
lysis of the GIC cultures featuring NAT12/NAA30
knockdown, showed increased expression of insulin-
like growth factor binding protein 3 (IGFBP3), the
inhibitor of the IGF1/MTOR pathway as compared to
NS controls (Additional file 8: Figure S6). Western blot
showed that total MTOR was not changed while the
levels of phospho-MTOR (Ser2448) were reduced in
Fig. 4 Functional effects of knockdown of NAT12/NAA30 in GIC cultures. a, Calorimetric XTT assay was used for the quantitative assessment of cell
viability. Analysis demonstrated a significantly lower percentage of viable cells in the knockdown cultures KD1 and KD2 compared to the NS
control. Error bars indicate standard deviation (n = 3). Asterisks signify p-values < 0.05. b, A sphere-forming assay was used to assess the ability of
the GICs to form colonies. Sphere number was decreased by 50-71 % in the knockdown cultures compared to the NS control. Error bars indicate
standard deviation of three independent experiments. Asterisks signify p-values < 0.05. c, Images of wells obtained from a sphere-forming
experiment showing far less spheres in KD1 and KD2 than NS control. d, Kaplan-Meier survival plot demonstrates that control animals (NS) died
much earlier than GIC cultures (KD1 and KD2) featuring NAT12/NAA30 knockdown. Median survival in days for each group is shown in the plot.
e-f, GIC cultures featuring NAT12/NAA30 knockdown (KD1 and KD2) had decreased mitochondrial hypoxia tolerance. Error bars indicate standard
deviation of more than 20 cells from at least four independent experiments (p-value < 0.01)
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the knockdown cultures (Fig. 5a). Western blot analysis
of selected important factors in the mTOR/AKT path-
way is provided in Additional file 9: Figure S8C.
One of the key features of GICs is the high expression
levels of the pluripotency marker nestin (NES) and that
they can be differentiated into a neuronal or glial lineage
[5, 27]. Upon differentiation the proliferative capacity of
these cells is lost while the levels of the neuronal marker
β3-tubulin (TUBB3) and the astrocytic marker GFAP
increase [27]. As we have shown NAT12/NAA30 knock-
down reduced GIC proliferation (Fig. 4a-b). Thus, we
wanted to investigate whether knockdown of NAT12/
NAA30 altered the expression levels of the aforementioned
markers towards a more mature cell type. Interestingly, in
both knockdown cultures GFAP was highly up-regulated
while the expression of NES and TUBB3 remained
unchanged as shown by qPCR analysis (Fig. 5b). However,
the expression of nestin at the protein level was reduced in
the knockdown cultures (Additional file 9: Figure S8B).
Western blot showed a so far undescribed variant of GFAP
(30 kDa) highly upregulated in the knockdown cultures
(Fig. 5c).
We have tested the expression of stem cell related
genes in the NAT12/NAA30 knockdown cultures. Flow
cytometric analysis showed that the CD133+ population
was depleted in both knockdown cultures compared to
the NS control (Additional file 11: Figure S10). We did
not detect the expression of CD15 in T65 (results not
shown). We also evaluated the expression of NANOG,
POU5F1/OCT4, SOX2 and MYC using microarrays.
None of these genes were differentially regulated at the
mRNA level in the knockdown cultures (Additional file
9: Figure S8C). However, the levels of SOX2 protein
were slightly decreased in the two knockdown cultures
as shown by western blot (Additional file 9: Figure S8B).
Western blot analysis further revealed that the levels
of active β-catenin (active CTNNB1/ABC), phospho-p70
S6 kinase (Thr389), phospho-STAT3 (Ser727), GLI1 and
CCND1 and several other proteins were only slightly
affected or not altered in the knockdown cultures
(Additional file 8: Figure S8A-B).
Discussion
GBM remains one of the most aggressive human can-
cers. Accumulating evidence supports the role of GICs
in disease progression, tumor cell invasion and the tu-
mor’s notorious resistance to chemo- and radiotherapy.
Fig. 5 Analysis of genes and pathways downstream from NAT12/NAA30. a, Western blot showing the expression of MTOR, pMTOR-Ser2448, p53
and ACTB (ACTIN) proteins. b, Relative expression of GFAP, NES and TUBB3 were measured by qPCR (normalized to NS). P values in this experiment
were as follows: p(GFAPv1) = 0, p(GFAPv2) = 0, p(NES) = 0.926, p(TUB3) = 0.348. Asterisks correspond to p values and indicate level of significance.
**** = (p < 0.0001). Additional details of the statistical analysis can be found in Additional file 4. c, Western blot showing the protein expression of
NAT12/NAA30, GFAP and ACTB in the knockdown cultures KD1 and KD2, NS culture, GIC culture T65 and NSCs. d, Western blot showing the
expression of HIF1a and ACTB in both knockdown cultures and controls
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Consequently, new molecular therapies against GBM
would also need to target this cell population.
Recently, protein Nt-acetylation has been implicated
in cancer development [16]. In the present study we
analyzed the expression of several NATs in GIC cul-
tures and GBM tissues showing which of these are co-
expressed and thus might be functionally redundant
(Fig. 1b-c and Additional file 4: Figure S2). We also
show that the increased expression of several NATs in
GBM tissues is associated with poor patient survival
and that these enzymes may be relevant as new poten-
tial therapeutic targets. To further reinforce the validity
of our study we used NSC cultures isolated from
several different regions of the brain as controls. We
identified NATs whose expression was significantly
down- or up-regulated in GBM and GICs (Additional
file 3: Figure S1).
By detailed expression analysis of NAT12/NAA30 in
tissues and cell cultures (GIC and NSC cultures, and
NFCs), we detected the presence of alternative tran-
script(s) that had 3’UTR regions of variable length
(Fig. 1d). We have demonstrated that these were differ-
entially regulated in GICs compared to NSCs. Espe-
cially the distal 3’UTR of NAT12/NAA30 was strongly
down-regulated in GBM and GIC cultures as shown by
two independent methods (microarray and qPCR)
(Fig. 1a and d). Moreover, public database mining re-
vealed that the decreased expression of the distal
3’UTR region correlated with a shorter survival of gli-
oma patients (Additional file 5: Figure S3A). Several
studies have shown that mRNA isoforms with differ-
ences in their 3’UTRs have different stability and trans-
lational activity [34–36]. In yeast it was found that
shorter mRNAs more frequently formed a closed-loop
structure that enhanced protein translation [37]. Mayr
et al. studied 27 cancer cell lines from different tissues
and showed that shortening of the 3’UTR in the tested
mRNAs seemed to be important for activation of onco-
genesis [38]. Shortening of the 3’UTRs resulted in
enhanced translation in some of these cancer cell lines.
More importantly, shorter mRNAs had greater stability
and produced more protein [38]. Another study re-
ported that shortening of 3’UTRs correlated with poor
patient survival in breast and lung cancer [39]. To our
knowledge we are the first to report the existence of an
analogous mechanism associated with GBM and GICs.
In the present work we show that the up-regulation of
NAT12/NAA30 at the protein level in GICs is not
caused by the increased levels of the steady state
mRNA but rather by other mechanisms such as short-
ening of the 3’UTR and possibly greater stability of
mRNA. Other processes involved in the complex regula-
tion of NAT12/NAA30 expression might be alternative
splicing, alternative poly-adenylation sites (Stangeland,
unpublished), and the presence of regulatory and/or cod-
ing sequences within the 3’UTR.
Human NAT12/NAA30 is known to be present in the
cytoplasm [23–26]. Our data show that it is also located
in the nuclei of GICs and some NSCs (Fig. 2i and k).
The transport of proteins from the cytosol to the nucleus
is a tightly regulated process facilitated by importins [40].
NAT12/NAA30 contains a nuclear localization signal
(RRGYIAMLAVDSKYRRN at 243 according to pSORT
II, http://psort.hgc.jp/) that confers a high probability of
being imported to the cell nuclei. It has also been
reported that 3’UTRs of other genes contain regulatory
regions that influence nuclear export and subcellular
localization [41]. The observed differential subcellular
localization of NAT12/NAA30 in the nucleus is novel
and might imply an additional role for NAT12/NAA30.
Another member of the NAT family, NAT-D, is known to
acetylate histones H2A and H4 [42]. Whether NAT12/
NAA30 protein can have a similar role remains to be
shown.
Furthermore, evaluating the staining pattern of
NAT12/NAA30 in GBM biopsies led to an interesting
observation (Fig. 2b-f ). NAT12/NAA30 was found to
be expressed predominantly in cells surrounding blood
vessels. In this perivascular region the GBM cells have
a much stronger expression of nestin than in other
parts of the tumor specimen. Co-staining with these
two markers showed a large degree of overlap in the
GBM cells around blood vessels. Recently, it was shown
that nestin regulates stemness, cell growth and invasion
in GBMs [43]. The authors reported that the overex-
pression of NESTIN increased cell growth, sphere
formation and cell invasion while depletion of NESTIN
resulted in decreased expression of stem cell markers.
The expression of nestin has been found to be an inde-
pendent prognostic factor in glioma patients [44]. Since
GICs are believed to reside in the perivascular niche of
the tumor [10–12], our immunolabeling might indicate
that NAT12/NAA30 is predominantly expressed in an
immature cell types in GBM.
RNAi-mediated gene silencing of NAT12/NAA30
enabled us to obtain a stable knockdown at both tran-
script and protein level as determined by qPCR, west-
ern blot and immunolabeling (Fig. 3). NATs are
evolutionarily highly conserved [17, 22]. The partial
knockdown we obtained might be explained by selec-
tion mechanisms having enabled GICs to avoid the
lethality that would result from total NAT12/NAA30
knockdown. Nevertheless, functional analysis of the
knockdown cultures revealed a clear phenotype with
restricted cell growth in vitro and in vivo (Fig. 4a-d).
Reduced sphere-forming ability in the knockdown cul-
tures was stable across passages. This finding is espe-
cially important because sphere formation has been
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reported to be an independent predictor of clinical out-
come [45].
The number of spheres is assumed to be both an indi-
cator of the aggressiveness of the tumor and the number
of tumor initiating cells. The ability to form spheres
strongly correlates with tumor growth and survival also
in animal models [46]. Our results from intracranial
transplantation into SCID mice were in agreement with
this as mice transplanted with GICs featuring NAT12/
NAA30 gene knockdown survived significantly longer
than controls. Altogether 3/11 mice did not form tumors
until the end of the observation period in the NAT12/
NAA30 knockdown group while all 6/6 mice died from
tumors in the control group.
There are few known substrates of NAT-C, but based
on the Nt-amino acid composition of target proteins
NAT-C can potentially Nt-acetylate up to 14.5 % of all
cytoplasmic human proteins [47]. The N-terminus of
MTOR protein begins with Met-Leu and is a strong
candidate as a direct substrate [23, 24]. In a study in
zebrafish TOR was suggested as a downstream target of
NAT-C [24]. The authors also demonstrated that over-
expression of TOR rescued the effect of depletion of a
NAT-C subunit [24]. Knockdown of MTOR is a critical
effector of the PIK3-AKT pathway which is dysregu-
lated in many cancers [48]. In GBM AKT-signaling
activity is significantly correlated with phosphorylation
of MTOR [49].
In our study, knockdown of NAT12/NAA30 led to
decreased levels of phospho-MTOR (Ser2448), while
the total MTOR levels remained unchanged (Fig. 5a).
Phospho-MTOR (Ser2448) binds to the effector com-
plexes mTORC1 and mTORC2 and is important for
mTORC1 activity [50]. Implication of MTOR as a (dir-
ect or indirect) target of NAT12/NAA30 was further
supported by the expression analysis that showed
increased levels of IGFBP3, an inhibitor of IGF1/MTOR
pathway, in the cell cultures featuring NAT12/NAA30
knockdown (Additional file 8: Figure S6).
Our results also indicate that NAT12/NAA30 acts via
the p53 pathway in GICs. In addition to an increment
in p53 protein levels in the knockdown cultures we also
provide evidence for dysregulation of the p53 pathway
genes. Genes involved in cell-cycle regulation, apoptosis
and DNA repair were those that suffered the most
substantial expressional alteration (Additional file 8:
Figure S6). We also show that NAT12/NAA30 affects a
considerable number of genes that regulate cell prolif-
eration and protein kinases.
We investigated the expression of stem cell related
genes in NAT12/NAA30 knockdown cultures. Of the
tested stem cell markers, we could detect reduced levels
of nestin and SOX2 at the protein level. The knockdown
of NAT12/NAA30 also reduced the percentage of CD133+
cells. Our data thus indicate the effect of NAT12/NAA30
knockdown on stemness in GICs.
A previous study has shown that mitochondrial pro-
teins are substrates of NAT12/NAA30 [22]. Interestingly,
we found that knockdown of NAT12/NAA30 in GICs
causes a more abrupt and severe mitochondrial mem-
brane depolarization compared to the NS control cul-
tures when these cells are exposed to hypoxia. This
indicates a reduced mitochondrial tolerance to acute
hypoxia upon NAT12/NAA30 knockdown. This notion
was further supported by microarray analysis showing
that the role of NAT12/NAA30 in hypoxia response
involves HIF1α and several other genes (Additional
file 10: Figure S9). Importantly, western blot analysis
confirmed the reduced expression of HIF1α protein
(Fig. 5d). Hypoxia induced factors are key mediators
in the response of cancer stem cells to hypoxia [32,
51]. Several studies have pointed out that GICs reside
in the hypoxic regions of GBMs [33] and that hypoxia-
induced molecular changes regulate and maintain the
phenotype of GICs [52]. This might imply that targeting
NAT12/NAA30 increases the vulnerability of GICs to hyp-
oxic conditions.
Conclusions
Although N-terminal acetylation complexes have lately
received a lot of attention, the functional role of the
NAT-C complex in cancer stem cells has not been inves-
tigated. In our work, we show that the knockdown of its
catalytic subunit, NAT12/NAA30, reduced tumorigenic
features of GICs and confirmed that MTOR and HIF1α
are downstream targets of NAT12/NAA30 in GICs. We
therefore propose that, NAT12/NAA30, might serve as a
potential therapeutic target in GBM. Our study further
indicates involvement of NAT12/NAA30 in gliogenesis
and regulation of the p53 pathway. Specific inhibitors
against NATs are under development [53] and might
represent promising candidates for clinical testing.
Materials and methods
Tissue specimens and cell culture
Tissue specimens were harvested from consenting pa-
tients after approval by the Norwegian National Commit-
tee for Medical Research Ethics. Tumor biopsies were
obtained as a part of surgical procedures for treating
GBM. Normal brain tissue (SVZ, HPC, GM and WM)
was obtained from fresh human temporal lobes surgically
resected to treat medically refractory epilepsy. All biopsy
specimens were evaluated by neuropathologists.
Tumor biopsies underwent mechanical dissociation and
Trypsin-EDTA (Gibco, Life Technologies, NYC, NY, USA)
was added for enzymatic dissociation. Subsequently, 2 mg/
ml human albumin (Octapharma pharmazeutika produk-
tionges, Vienna, Austria) was used to block the Trypsin
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effect and the cells were washed in L-15 (Lonza, Basel,
Switzerland) before being plated in serum-free neuro-
sphere medium containing 10 ng/ml basic fibroblast
growth factor (bFGF) and 20 ng/ml epidermal growth
factor (EGF) (both R&D Inc., Minneapolis, MN, USA),
B27-supplement (1:50, Invitrogen, Carlsbad, CA, USA),
100 U/ml Penicillin/streptomycin (Lonza), 1 ng/ml Hep-
arin (Leo Pharma, Ballerup, Denmark) and 8 mM Hepes
(Lonza) in Dulbecco’s modified essential medium with
nutrient mix F-12 and Glutamax (DMEM/F12, Invitrogen)
[24, 25]. Dissociated GBM biopsies grown as free-
floating spheres in serum free-medium containing mi-
togens (EGF and bFGF) are highly enriched for GICs
[7, 54]. The GIC cultures used in this current work
(T65, T08, T59) were analyzed for the expression of
stem cell markers by flow cytometry and showed high
expression of CD44, CXCR4, CD166 and CD9 while
the expression of CD133 and CD15 was variable [55].
Immunolabeling showed that most cells were nestin
and Sox2 positive (Additional file 6: Figure S4H-I,
Stangeland, B. et al., in press). The cells were cultured in
75 cm2 non-treated flasks (Nunc, Roskilde, Denmark) at a
density of 105 cells/ml and supplemented with EGF and
bFGF twice a week. When the spheres reached
approximately 100 μm in diameter they were dissociated
into single cells as previously described [28]. We have pre-
viously shown that the GIC cultures T65, T08, TC3 and
TC4 formed invasive tumors upon orthotopic transplant-
ation to SCID mice [55, 56].
NFCs (ReNcell VM Human Neural Progenitor Cell
Line, SCC008, Merck Millipore, Darmstadt, Germany)
were cultured as spheres in serum-free Neurobasal A
medium (Gibco) containing B27 (Gibco), 2 mM L-
glutamine, 10 ng/ml bFGF, and 20 ng/ml EGF (both
from R&D Systems).
Tissue specimens from the adult human brain were
dissociated into single cells and cultured according to
our FAILSAFE protocol (1 % FBS, 10 ng/ml bFGF and
20 ng/ml TGF α) that ensures robust long-term propa-
gation of multipotent stem cells from the adult human
brain [57].
Microarray analysis and public database mining
Microarray analysis was performed using Illumina gene
chip. The data were quantile normalized and analyzed
using J-Express (Molmine, Bergen, Norway) analysis soft-
ware. We used published microarrays [57] with submis-
sion numbers GSE41470 (encompassing GSE41390, and
GSE41394), GSE53800 (GSM1301030, GSM1301033, GS
M1301042) as well as the microarrays submitted in
connection with this work GSE60818 (encompassing
GSE60705 and GSE60706). For more information on
microarray analysis see Additional file 1: Figure S1 and
Additional file 2: Figure S2 and Additional file 3 and
Additional file 7.
REMBRANDT: Microarray data from the Repository for
Molecular Brain Neoplasia Data (REMBRANDT, National
Cancer Institute, 2005, http://rembrandt.nci.nih.gov) were
accessed on January the 15th 2014. Hierarchical clustering
with distance matrix and the K-means clustering of the
NAT genes’ expression were performed using J-Express
software (Molmine). For calculation of statistical parame-
ters, we used Graphpad Prism (www.graphpad.com).
Western blot and quantification of protein expression
The cells were homogenized by triturating in Cell
Extraction Buffer (Mammalian cell extraction kit,
Biovision, Milpitas, CA, USA) and centrifuged through a
QIAshredder (Qiagen, Venlo, Netherlands). For HIF1α
and the western blots with phospho-proteins, the cells
were homogenized in 10 mmol/L Tris–HCl (pH 7.4), 1 %
SDS, 10 mmol/L NaF, and 2 mmol/L Na3VO4 as previ-
ously described [58]. 20–40 μg of whole protein extract
were mixed with loading buffer (NuPAGE, Invitrogen)
and loaded onto a 4–12 % gradient Nu-PAGE gel (Invitro-
gen). Protein gels were blotted onto 0.45 μm PVDF mem-
branes (Invitrogen). Membranes were blocked with 5 %
skimmed milk in TBS/0.1 % Tween 20 (TBST) and
probed with primary antibodies diluted in the same solu-
tion. Primary antibodies from Cell Signaling Technolo-
gies (CST, Danvers, MA, USA) were incubated in bovine
serum albumin (BSA) according to recommended proce-
dures. For a complete list of the antibodies used in this
study see Additional file 12. For a complete list of the
antibodies used in this study see Additional file 12. The
blots were developed using the Lumiglo Reserve CL Sub-
strate kit, and detected using the Epi Chemi II Darkroom
(UVP-Laboratory Products, Upland, CA, USA). The in-
tensities of the protein bands were quantified using
Photoshop (Adobe, San Jose, CA, USA), background cor-
rected and normalized to the intensities of the corre-
sponding ACTB bands, so that the relative protein
expression (RPE) could be calculated (RPEprotx = PEprotx/
PEACT).
RNA isolation and real-time quantitative
reverse-transcription PCR (qPCR)
Total RNA was isolated using an RNeasy Mini Kit and
QIAshredder (Qiagen). For cDNA synthesis, experimen-
tal set up and oligonucleotide design we used the pro-
cedure previously described [59]. For expression analysis
of NAT12/NAA30 we used seven sets of oligonucleo-
tides covering translated and non-translated regions of
the reference sequence NM_001011713.2. For oligo-
nucleotide sequence information see Additional file 3.
qPCR was performed on an ABI PRISM 7900HT PCR
machine (Applied Biosystems, Life Technologies, Foster
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City, Ca, USA) using SYBR Premix Ex Taq™ (Takara,
Otsu, Japan) or Taqman probes (Applied Biosystems)
according to the manufacturer's protocol. For analysis of
the NAT12/NAA30 coding regions we used the following
Taqman probes: ex2-3 (Hs02340852), ex3-4(Hs02340853)
and ex4-5(Hs02340854). Crossing point (CP) values were
generated using second-derivative calculation software
(SDS2.2). Gene expression levels in GIC cultures were
calculated using two house-keeping genes and multiple
controls (values obtained for all tested NSCs and NFCs).
For analysis of qPCR results we used 2-ΔΔ CT-method
and REST software [60].
RNAi-mediated gene knockdown
GIC culture T65 was used to establish stable NAT12/
NAA30 knockdown cultures using shRNA1 (RHS4430-
99149700; Clone ID V2LHS_180063), shRNA2 (RHS4
430-99137454; Clone ID V2LHS_180058) and a non-
silencing (NS) shRNA as a control (RHS4346) (all from
Open Biosystems, Thermo Scientific, Huntsville, AL,
USA). Cell cultures harboring shRNA constructs 1 and 2
are referred to as KD1 and KD2 respectively.
Production of virus in the 293 FT cell line using plas-
mid DNA and concentration of virus was done as fol-
lowing: Nine μg of plasmid DNA was transfected into
the 293FT cell line using Arrest-In transfection reagent
(according to the manufacturer’s protocol). Viral super-
natants were collected after 48 and 72 h, centrifuged at
3000 rpm for 20 min at 4 °C and filtered through a
sterile 0.45 μm low protein binding filter (Sarstedt,
Nümbrecht, Germany). The virus was then concen-
trated in sterile SW28 ultracentrifuge tubes by ultracen-
trifugation (Beckman Optima™ LE-80 K ultracentrifuge,
Fullerton, CA, USA) equipped with a SW-28 rotor at
23,000 rpm for 1.5 h at 4 °C. The pellet was resus-
pended in 200 μl of DMEM and aliquots of the concen-
trated virus were stored at −80 °C. GSC cultures
(10×104 cells/ well) were then transduced in 24-well
plates by adding 10 μl concentrated virus/well and the
cells were incubated for 48 h at 37 °C in 5 % CO2.
Three to five days after transduction, GFP positive cells
were selected by FACS sorting using a FACS Diva cell
sorter (Becton Dickinson, Franklin Lakes, NJ, USA)
equipped with an argon ion laser, ‘TurboSort Plus’ op-
tion, and Diva software (Becton Dickinson). Alterna-
tively, the cells were selected in 2 μg/ml Puromycin
(Sigma-Aldrich, St. Louis, MO, USA) for 3–4 weeks be-
fore use for functional assays.
Cell viability, apoptosis and sphere-forming assay
For analysis of cell viability we used a colorimetric test
based on tetrazolium salt – XTT (Roche Diagnostics,
Indianapolis, IN, USA). Briefly, after sphere dissociation
single cells were plated in neurosphere medium at a
density of 1×104 cells per well in a flat-bottom 96-well
plate (Sarstedt). Cells were incubated overnight and
XTT-reagents added as recommended by the manufac-
turer. The colorimetric changes (absorbance) were
measured after 24 h at 490 nm using a plate reader
(Victor™ X5 Multilabel Plate Reader, Perkin Elmer 2030,
Waltham, MA, USA). Five wells were evaluated for
each cell culture. All results were presented as a mean
of three independent experiments ± standard deviation.
P-values were calculated using unpaired t-test with
Welch’s correction.
Apoptosis was assessed using a fluorimetric assay
which measures the activity of activated caspases (Roche
Diagnostics). 1×104 cells were plated per well in a flat-
bottom 96-well plate (Sarstedt) and incubated overnight
before adding the reagents as recommended by the
manufacturer. The fluorimetric changes were measured
after 24 h at 485/535 nm using a plate reader (Victor™
X5 Multilabel Plate Reader). Five wells were evaluated
for each cell culture.
The sphere-forming assay was done by seeding single
cell suspensions containing 500 cells per well in ultra-
low attachment flat bottom 96-well plates for 10 days
(Sarstedt). Subsequently, the plates were imaged using
GelCount™ (Oxford Optronics, Abington, UK). Only
spheres >50 μm were taken into consideration and 10
wells were evaluated for each cell culture. The number
and the size (average area) of spheres were measured
using software supplied by the manufacturers. All results
were presented as a mean of five independent experi-
ments ± standard deviation. P-values were calculated
using unpaired t-test with Welch’s correction.
Intracranial transplantation to SCID mice
All animal procedures were approved by the National
Animal Research Authority. C.B.-17 SCID male mice
(8–9 weeks old) were obtained from Taconic (Ejby,
Denmark). They were acclimatized for > 1 week and
divided into 3 groups: (i) T65 NS cells (n = 6), (ii) T65
KD1 cells (n = 6) and (iii) T65 KD2 cells (n = 6).
T65 GIC cultures were sorted by FACS after viral
transduction and cultured for a few passages before
transplantation. After tumor sphere dissociation, cells
were counted and plated at a low density for overnight
incubation. Prior to the inoculation of cells, mice were
anesthetized and placed in a stereotactic frame (Kopf In-
struments, Tujunga, CA, USA) and ~3×105 incubated
cells were inoculated into the right striatum (AP 0 mm,
RV 2 mm, ML 2 mm) using a Hamilton syringe and nee-
dle (Hamilton, Bonaduz, Switzerland) [28].
All animals were monitored for adverse effects and
examined regularly for general appearance, signs of dis-
tress, and weight measurements taken. Mice were sacri-
ficed when they lost >10 % of their bodyweight and
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developed neurological symptoms. Brains were harvested
and further processed for HE-staining as described pre-
viously [28]. Results for all groups are presented as
median survival in days. Log-rank test was used to cal-
culate the level of significance.
Mitochondrial depolarization assay
After passage, KD1, KD2 and NS cultures were seeded
on fibronection-coated cover slips, and cultured in neu-
rosphere medium in separate culture dishes for 1–6 days
before experiments.
For each experiment, a cover slip was removed from
its cell culture dish, and mounted in the microscopy
chamber. Artificial CSF (aCSF) with the fluorescent
cationic dye Rhodamine 123 (30 μM) (Invitrogen) was
added to the chamber, and cells were loaded with dye
for 15 min at 37 °C on the microscope. The chamber
was covered with a lid, and subsequently perfused with
air and 5 % CO2 for maintenance of appropriate pH.
After loading of dye, the chamber was perfused with
aCSF at a flow rate of approximately 1 ml/min. Imaging
was started after at least 10 min of flow. Healthy looking
cells were chosen by the criteria clear cell membrane
and intact processes. Live imaging was performed using
an Olympus IX81 inverted microscope equipped with a
MT20 fluorescence light unit and Olympus xcellance
software. Images were captured every 15 s. Rhodamine
123 (Rh123) used at 30 μM concentration accumulates
in healthy mitochondria and is released to the cytosol
upon depolarization of the mitochondria [61]. This
release is shown by increment in fluorescence from the
cell. Since all cells expressed GFP, the red spectrum of
Rh123 was recorded by using filters suitable for red
fluorescent protein.
The cells were exposed to severe hypoxia for 15 min.
Hypoxia was obtained by removing most of the oxygen
by nitrogen perfusion of the flow solution. The oxygen
scavenger Sodium Dithionite (0.75 mM) (Sigma-Aldrich)
induced severe hypoxia. Control experiments were done
with Sodium Dithionite perfusing the fluid with oxygen
to control for any toxic effects other than caused by hyp-
oxia. These control experiments did not show toxic
effects on mitochondrial function. The protonophore
Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone
(FCCP) (1 μM) (Sigma-Aldrich) was applied before the
end of all experiments. FCCP fully depolarizes mito-
chondria, and thereby causes release of any remaining
dye from the mitochondria. In this way any remaining
mitochondrial membrane potential in the cell is revealed
by an increase in Rh123 fluorescence.
Immunolabeling
GIC cultures were plated in 24-well plates (Sarstedt) or
chamber slides (Sigma-Aldrich) pretreated with Retronectin
50 μg/ml (Takara) and incubated overnight to facilitate cell
adhesion. Cells were fixed with 4 % PFA and washed with
PBS. Tissue slides were fixed in 10 % buffered formalin and
washed with PBS. Immunolabeling was performed as previ-
ously described [62]. Briefly, permeabilization in 0.1 % Tri-
ton, was followed by blocking with 5 % BSA and 5 %
blocking serum, and incubations firstly with primary anti-
body in 0.1 % Tween-20 (o/n) and then with secondary
antibody (2 h). The protocol was slightly modified for the
co-staining of NAT12/NAA30 and CD31 and 0.1 % Triton
was replaced with 0.1 % (w/v) Saponin (Sigma-Aldrich).
After staining of nuclei with Hoechst 33342 (Invitrogen)
the slides were mounted with antifade reagent (ProLong
Gold, Invitrogen).
For detection of NAT12/NAA30 protein we used the
primary antibody #AV48508 [(Sigma-Aldrich), rabbit
1:200]. For confirmation of the obtained results we
used #NBP1-70631 [(Novus Biologicals, Littleton, CO,
USA), rabbit 1:200]. Immunofluorescence images
shown in the article were obtained with #AV48508.
We used primary antibodies against human nestin
(NES) [#ab6320 (Abcam, Cambridge, UK), mouse
1:400], CD31 [#ab54211 (Abcam), mouse 1:100] and
SOX2 [#AF2018 (R&D), goat 1:100].
Secondary antibodies were: Alexa Fluor 488 [#A-11059
(Invitrogen), donkey anti-mouse, 1:500], Alexa Fluor 555
[#A-31572 (Invitrogen), donkey anti-rabbit, 1:500], Alexa
Fluor 594 [#R37119 (Invitrogen), donkey anti-rabbit,
1:500], and Alexa Fluor 594 [#A-11058 (Invitrogen),
donkey anti-goat, 1:500].
Flow cytometry
Spheres from GIC culture T65 were dissociated into
single cells, and incubated overnight to recover. Cells
were pelleted, and incubated with primary conjugated
antibodies against CD133/2 –PE conjugated (Miltenyi
biotec) and SSEA1-PE (Becton-Dickinson). Cells were
then analyzed using a LSRII flow cytometer (Becton-
Dickinson).
Additional files
Additional file 1: Figure S1. Microarray analysis of the selected NAT
genes. A, Expression of NAA30/NAT12 in tissues and cells. Expression was
measured by microarray analysis of 17 cell cultures (NSCs, NFCs and GICs)
and four tissue specimens from normal and GBM tissues. Median
expression in cell cultures was 126.8 while in tissues it was 94.29 with p
value of 0.0013. B-H, Expression of the selected NATs in NSCs, GICs,
normal brain tissues, GBM and NFCs. P values were calculated using the
Mann Whitney test. Due to small sample sizes the p values proved
reliable only for GICs vs. NSCs and were as follows: p(NAT12)=0.023,
p(NAT6)=0.0002, p(NAT14)=0.78, p(NAT13)=0.3231, p(NAT8L)=0.0057,
p(NAT8)=0.0006, p(NAT8B)=0.003 and p(NAT10)=0.4331.
Additional file 2: Figure S2. K-means clustering of the expression data
for the selected NAT genes.
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Additional file 3: Supplementary File 1. Oligonucleotides and
microarray probes. (PDF 115 kb)
Additional file 4: Supplemetary File 2. Additional qPCR statistics for
Fig. 1, Fig. 3 and Fig. 5. (PDF 254 kb)
Additional file 5: Figure S3. Kaplan-Meier survival plot for NAT genes
(NAT12, NAT1, NAT2 and NAT10). P values (Log-rank test) signify the
differences in patient survival in the selected groups with the following
parameters: Up-Regulated: fold ≥ 2; Down-Regulated: fold ≥ 2. Reporter
Type: Affymetrix.
Additional file 6: Figure S4. Protein expression of NAT12/NAA30
detected with an anti-NAT12/NAA30 antibody (red) in biopsy specimens
from normal brain (A), in GBM (B), in NSC (C-D) and GIC cultures (E-F).
Cryostat sections with HE-staining from xenograft experiments showed
that the control cultures (T65 and T65 NS) form visible tumors upon
intracranial transplantation in contrast to the NAT12/NAA30 knockdowns
(KD1 and KD2) (G). High magnification images showed that tumor cells
are present in all groups even though the tumors are not visible in the
knockdowns. Protein expression of NESTIN in GIC culture T08 (H) and
SOX2 in T65 (I).
Additional file 7: Supplementary File 3. Functional annotation based
on the microarray analysis of NAT12/NAA30 knockdown cultures. (XLSX 201 kb)
Additional file 8: Figure S5-S7. Figure S5. NAT12/NAA30 knockdown
resulted in dysregulation of ribosome assembly as shown by microarray
analysis. Using the DAVID functional annotation tool we analyzed the
KEGG pathway “Ribosome” where 13 genes (p=5.6E-06) were differentially
regulated in KD1 and KD2. See also Supplementary File 3. Dysregulated
genes are marked with red asterisks. Figure S6. NAT12/NAA30 knockdown
resulted in dysregulation of the p53 pathway as shown by microarray
analysis. Using the DAVID functional annotation tool we analyzed the KEGG
pathway “p53” where 8 genes (p=3.1E-03) were differentially regulated in
KD1 and KD2. See also Supplementary File 3. Dysregulated genes are
marked with red asterisks. Figure S7. NAT12/NAA30 knockdown resulted in
dysregulation of sphingolipid metabolism as shown by microarray analysis.
Using the DAVID functional annotation tool we analyzed the KEGG pathway
“Sphingolipid metabolism” where 6 genes (p=4.8E-03) were differentially
regulated in KD1 and KD2. See also Supplementary File 3.
Additional file 9: Figure S8. Expression of the selected genes and
proteins in the NAT12/NAA30 knockdown cultures. A, Western blot
showing that the protein levels of active β-Catenin (ABC), phospho-p70
S6 kinase (Thr 389), phospho-STAT3 (Ser727) and GLI1 were slightly
affected or not altered in the knockdown cultures. The signals obtained
with Anti-SHH and Anti-phospho-p53 (Ser15) were below the detection
level of western blot (not shown). For a complete list of ABs see
Supplementary File 4. B, Western blots showing the expression of neural
stem cell markers SOX2 and NESTIN, proteins representing hypoxia
response (KCNMA1), cell cycle (CCND1) and ACTB (ACTIN). C, Western
blots showing the expression of p-AKT (Ser473), total AKT, p-AKT (Ser308),
p-p4E-BP1 and total p4E-BP1. D, Expression of selected stem cell genes
SOX2, NANOG, POU5F1/OCT4, MYC and CCND1 on microarrays (n=4 for
each cell culture). None of the selected genes were differentially
regulated in the NAT12/NAA30 knockdown cultures. The bottom and top
of each box indicate the 25th and 75th percentile (the lower and upper
quartiles, respectively), and the band near the middle of the box
represents the 50th percentile (the median). Interestingly, the knockdown
strength was in correlation with the effect on downstream genes. In the
KD2 culture that exhibited stronger knockdown effect at the protein level
and better reduction in cell viability and number of spheres we could also
detect decreased levels of GLI1, nestin and phospho proteins such as
phospho-AKT (Ser308) and p-4E-BP1(Thr37/46) (Figure S8 A-C).
Additional file 10: Figure S9. NAT12/NAA30 knockdown resulted in
dysregulation of the hypoxia response pathway as shown by microarray
analysis. Asterisks signify p values and indicate level of significance.
*=(p≈0.01-0.05), **=(p≈0.001-0.01).
Additional file 11: Figure S10. NAT12/NAA30 knockdown resulted in
reduction of CD133+ cells as shown by flow cytometry.
Additional file 12: Supplementary File 4. List of antibodies used for
western blot. (DOCX 53 kb)
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